The dramatic responsiveness of EGFR-mutated NSCLC to small moleculeinhibitors of the EGFR kinase has provided a paradigm for the targeted therapy ofepithelial cancers and has established a new standard of care for a genetically definedsubset of patients with lung cancer. This evidence concerns the gene EGFR and lung cancer.